Concept

Pumitamig Therapy

ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor / ROSETTA Lung-02: Pumitamig

"First-line therapy with the bispecific antibody pumitamig was associated with “encouraging” overall response rates in both squamous cell and nonsquamous NSCLC regardless of PD-L1 expression levels, according to dose-optimization findings from the ROSETTA Lung-02 trial.3\n\n“This is the first global data for specifically an anti-PD-L1 VEGFA bispecific antibody in frontline metastatic non-small cell lung cancer, in addition to chemotherapy,” reported study coauthor Solange Peters, MD, PhD, of Lausanne University in Switzerland. Encouraging response rates were seen across histology and PD-L1 levels, along with a manageable safety profile and no new safety signals, she said.\n\nPumitamig reverses tumors’ immunosuppression of immune T-cells with PD-L1 checkpoint blockade within the tumor microenvironment and neutralizes VEGFA normalization of tumor vasculature, Dr Peters explained."

Related Ideas

  • Response RatesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Safety SignalsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Dynamic CtdnaFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
  • Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
  • Survival OutcomesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
  • TRITON FindingsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
  • Trial ResultsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
  • Safety OutlookASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
Pumitamig Therapy | ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor | Bifalgorithm | Bifalgorithm